Inion Oyj - Company Announcement

Inion to Present at Second Annual Piper Jaffray Health Care Conference on 21 June 2007

Inion to Present at Second Annual Piper Jaffray Health Care Conference on 21  
                                   June 2007                                    


Tampere, Finland and Takeley, UK. 18 June 2007… Inion Oy (LSE: IIN.L) (“Inion”),
a company focused on the development of novel biodegradable medical implants,   
announces that its CEO, Mr Chris Lee, will be presenting at the Piper Jaffray   
Heath Care conference in London on Thursday 21 June 2007 at 4.40pm BST (UK time)
(11.40am EST). The presentation is being webcast live and can be accessed using 
the following link, which is also available through the Investors section of the
Inion website (www.inion.com). The link also provides access to a recording of  
the webcast, which is available for 30 days from 21 June 2007 from 6.00pm BST.  

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=INOYF.PK&item_id=157382
6                                                                               

                                    - ends -                                    

For further information, please contact:                                        

--------------------------------------------------------------------------------
| Inion Oy	                                  | Tel: +44 (0)1279 874 222        |
| Chris Lee, Chief Executive Officer         |                                 |
| Julien Cotta, Chief Financial Officer      |                                 |
--------------------------------------------------------------------------------
| Citigate Dewe Rogerson                     | Tel: +44 (0)207 638 9571        |
| Mark Swallow / Helena Galilee / David      |                                 |
| Dible                                      |                                 |
--------------------------------------------------------------------------------

About Inion (www.inion.com)                                                     

Inion Oy is a medical devices company focused on the development and successful 
commercialisation of innovative biodegradable and bioactive implants in key     
target markets. The Company's target segments are Spine and Specialty           
Orthopaedics.                                                                   

Inion's core expertise and technology lies in the design and manufacture of     
innovative biodegradable plates, screws, pins and membranes, which are used to  
enhance the healing of bone or soft tissue injuries to the skeleton, such as    
those caused by trauma or by reconstructive surgery. Inion implants are made    
from its proprietary Inion Optima™ family of biomaterials, with properties      
tailored for specific surgical applications, in terms of strength, flexibility  
and rate of degradation.                                                        
                                                                                
Inion is also focused on developing proprietary new bioactive and biodegradable 
biomaterials that promote bone healing and accelerate patient rehabilitation.   

Inion was incorporated in early 2000 and listed on the Official List of the UK  
Listing Authority in December 2004. The Company has an office and an R&D        
facility in the UK and head office, R&D and production facilities in Tampere,   
Finland.                                                                        
                                                                                

This announcement includes "forward-looking statements" which include all       
statements other than statements of historical facts, including, without        
limitation, those regarding the Group's financial position, business strategy,  
plans and objectives of management for future operations (including development 
plans and objectives relating to the Group's products), and any statements      
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will", 
"can", "may", "anticipates", "would", "should", "could" or similar expressions  
or the negative thereof. Such forward-looking statements involve known and      
unknown risks, uncertainties and other important factors beyond the Group's     
control that could cause the actual results, performance or achievements of the 
Group to be materially different from future results, performance or            
achievements expressed or implied by such forward-looking statements. Such      
forward-looking statements are based on numerous assumptions regarding the      
Group's present and future business strategies and the environment in which the 
Group will operate in the future. Among the important factors that could cause  
the Group's actual results, performance or achievements to differ materially    
from those in forward-looking statements include those relating to Inion's      
funding requirements, regulatory approvals, reliance on third parties,          
intellectual property, key personnel and other factors. These forward-looking   
statements speak only as at the date of this announcement. The Group expressly  
disclaims any obligation or undertaking to disseminate any updates or revisions 
to any forward-looking statements contained in this announcement to reflect any 
change in the Group's expectations with regard thereto or any change in events, 
conditions or circumstances on which any such statements are based. As a result 
of these factors, prospective investors are cautioned not to rely on any        
forward-looking statement.